Testing CS5007 for Advanced Solid Tumors
Part of Cancer clinical trials.
This is an early-stage study testing a new drug called CS5007 in people with advanced cancer that cannot be surgically removed. The goal is to understand how safe the drug is and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid cancer (not treatable by surgery alone) confirmed by biopsy or lab test
- Your cancer has at least one tumor that can be measured on imaging scans
- You are healthy enough to do daily activities with minimal assistance (ECOG score 0–1)
- Your major organs (heart, lungs, liver, kidneys) are working well enough
- You are expected to live at least 3 months
- If able to have children, you agree to use effective birth control for 6 months after treatment ends
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CS2009 for people with advanced solid tumors that haven't responded to other treatments. It aims to see if the drug is safe and effective.
This Phase 1 study tests whether a new drug called SYS6051 is safe and effective for people with advanced solid tumors (cancer that has spread). Researchers will evaluate how well your body tolerates the drug and monitor for side effects.
This trial tests a new drug called SKB500 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and may help shrink tumors.
This trial tests a new drug, CM518D1, for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective, and may offer a new option for those who have few choices left.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This study tests a new drug called FS-207 in patients with advanced solid tumors that have a specific genetic feature (high microsatellite instability) and have stopped responding to prior immunotherapy. The goal is to see if FS-207 is safe and whether it can help shrink these tumors.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.